Management of end-stage liver disease in HIV-infected patients

Current Opinion in HIV and AIDS

Volumn 2, Issue 6, 2007, Pages 474-481

  Agüero, Fernando ^a   Laguno, Montserrat ^a   Moreno, Asuncion ^a   Rimola, Antonio ^a   Miró, José M ^a,b   Miro J M ^a   Rimola, A ^a   Moreno, A ^a   Laguno, M ^a   Larrousse, M ^a   Blanco, J L ^a   Mallolas, J ^a   Cervera, C ^a   Tuset, M ^a   Monras, M ^a   Freixa, N ^a   Blanch, J ^a   Lanaspa, C ^a   De Lazzari, E ^a   Garcia Valdecasas J C ^a   Gatell, J M ^a   Tural, C ^c   Fuster, D ^c   Murillas, J ^d   Moitinho, E ^d   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

End stage liver disease; Hepatitis B virus; Hepatitis C virus; HIV infection; Liver transplantation; Mortality; Prognosis

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NEVIRAPINE; RITONAVIR;

CLINICAL FEATURE; DEVELOPED COUNTRY; DISEASE ASSOCIATION; END STAGE LIVER DISEASE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER DISEASE; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT INDICATION;

EID: 40349087348     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f0aadd     Document Type: Review

References (63)

1. Mohsen AH, Easterbook PJ, Taylar C, et al. Impact of human immunodeficiency virus (HIV) on the progression of liver fibrosis in Hepatitis C virus infected patients. Gut 2003; 52:1035-1040.
2. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257-265.
3. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
4. Rockstroh J, Mocroft A, Soriano V, et al. Influence of hepatitis C coinfection on HIV disease progression within the Eurosida Cohort. In: 9th European AIDS Conference. Warsaw, Poland, 25-29 October 2003. Abstract F12/4.
5. Konopnicki D, Mocroft A, De Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
6. Fung J, Eghtesad B, Patel-Tom K, et al. Liver transplantation in patients with HIV infection. Liver Transpl 2004; 10 (Suppl 2):S39-S53.
7. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
8. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
9. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-130.
10. Martinez E, Milinkovic A, Buira E, et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007; 8:251-258. This single-centre study showed clearly the increasing rate of ESLD as a cause of death in HIV-infected patients.
11. Rosenthal E, Pialoux G, Bernard N, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14:183-188.
12. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus, the D:A:D Study. Arch Intern Med 2006; 166:1632-1641. This international study is an excellent report on liver-related deaths in the HIV-infected population.
13. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41:779-789.
14. Shaw E, Castellote J, Santín M, et al. Clinical features and outcome of spontaneous bacterial peritonitis in HIV-infected cirrhotic patients: a case-control study. Eur J Clin Microbiol Infect Dis 2006; 25:291-298. This Spanish study analysed the different characteristics of SBP in the HIV-infected and HIV-negative populations.
15. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285-2293.
16. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20:49-57. This Spanish study described the prognostic factors of survival in co-infected patients with ESLD.
17. Maida I, Nunez M, Gonzalez-Lahoz J, Soriano V. Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation? AIDS Res Hum Retroviruses 2005; 21:599-601.
18. Ragni MV, Eghtesad B, Schlesinger KW, et al. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11:1425-1430.
19. Cardenas A, Gines P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 2005; 42 (Suppl 1):S124-S133.
20. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10 (2 Suppl 1):S115-S120.
21. Sogni P, Salmon-Céron D, Podevin P. Management of cirrhosis complications in HIV patients coinfected with hepatitis B or C virus. Presse Med 2005; 34:1579-1583.
22. Neff G, Shire N, Rudich M, et al. Outcomes among patients with end stage liver disease who are coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005; 41 (Suppl 1):S50-S55.
23. Bruno R, Puoti M, Sacchi P, et al. Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. J Hepatol 2006; 44:S146-S150. This is an excellent paper concerning the management of HCC in the HIV-infected population. The authors suggest that control liver ultrasounds should be performed every 3 months.
24. Han MK, Hyzy R. Advances in critical care management of hepatic failure with insufficiency. Crit Care Med 2006; 9:S225-S231.
25. Gaspari R, Avolio AW, Zileri Dal Verne L. Molecular adsorbent recirculating system in liver transplantation: safety and efficacy. Transplant Proc 2006; 38:3544-3551.
26. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85:498-502.
27. Pessione F, Ramond MJ, Njapoum C, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001; 34:121-125.
28. Hezode C, Lonjon I, Roudot-Thoraval F, et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003; 52:126-129.
29. Cooper C, Cameron DW. Effect of alcohol use on the impact of effective antiretroviral therapy for HIV co-infection on plasma HCV levels. Clin Infect Dis 2005; 41:S105-S109.
30. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42:63-71.
31. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089. This comprehensive review written by an international panel updates the recommendations for the essential areas of the HCV/HIV co-infection setting.
32. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19:221-240.
33. Everson G. Treatment of hepatitis C in patients who have decompensated cirrhosis. Clin Liver Dis 2005; 9:473-486.
34. Mauss S, Valenti W, DePhamphilis J. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-F25.
35. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection. 2006 Recommendations of the International AIDS Society - USA panel. JAMA 2006; 296:827-843.
36. Panel de expertos de GESIDA; Plan Nacional sobre el Sida. Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007). Enferm Infecc Microbiol Clin 2007; 25:32-53.
37. Terrault NA, Carter JT, Carlson L, et al. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006; 12:801-807.
38. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36:363-367.
39. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.
40. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in HIV and hepatitis C coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287.
41. Macias J, Mira J, Lopez Cortes L. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antiviral Therapy 2006; 11:839-846.
42. Wyles DL, Gerber J. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40:174-181.
43. Back D, Gibbons S. The University of Liverpool HIV drug interactions website. Available at: http://www.hiv-druginteractions.org/frames.asp? pharmacology/pharma_main.asp. [Accessed: August 2007]
44. O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). HIV Med 2005; 6 (Suppl 2):149-153.
45. Grossi PA, Tumietto F, Costigliola P, et al. Liver transplantation in HIV-infected individuals: results of the Italian National Program. Transplant International 2005; 18 (Suppl 1):11.
46. Miró JM, Torre-Cisneros J, Moreno A, et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain - March, 2005. Enferm Infecc Microbiol Clin 2005; 23:353-362.
47. Anonymous. Solid organ transplantation in the HIV-infected patient. Am J Transplant 2004; 4(Suppl 10):83-88.
48. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75:425-429.
49. Neff GW, Sherman KE, Eghtesad B, Fung J. Review article: current status of liver transplantation in HIV-infected patients. Aliment Pharmacol Ther 2004; 20:993-1000.
50. Radecke K, Fruhauf NR, Miller M, et al. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver Int 2005; 25:101-108.
51. Roland M, Stock PG. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006; 26:273-284.
52. Liu LU, Schiano TD, Lau N, et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant 2003; 3:1273-1277.
53. Roland M, Carlson L, Ragni M, et al. Solid organ transplantation in HIV-infected recipients: 47 cases in the HAART era. In: XIVth International AIDS Conference. Barcelona, Spain, 7-12 July 2002. Abstract MoOrB1060.
54. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188:1412-1420.
55. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9:239-247.
56. Norris S, Taylor C, Muiesan P, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10:1271-1278.
57. Vogel M, Voigt E, Schafer N, et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl 2005; 11:1515-1521.
58. Duclos-Vallee JC, Teicher E, Feray C, et al. Liver transplantation of HIV-HCV and HIV-HBV coinfected patients: a large experience in a single centre. Liver Transpl 2006; 12:C-103.
59. De Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6:2983-2993. This single-centre study focused on the negative impact of recurrent hepatitis C on co-infected recipients. Fourteen out of 27 patients died and 5-year survival was lower in co-infected patients (33%) in comparison with mono-infected patients (72%).
60. Castells L, Esteban J, Bilbao I, et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antiviral Therapy 2006; 11:1061-1070.
61. Miró JM, Montejo M, Castells L, et al. 3-Year survival of HCV-HIV coinfected liver transplant recipients (OLT) is similar to that of HCV monoinfected recipients. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, 17-20 September 2007. Abstract 2352.
62. Miro JM, Aguero F, Laguno M, et al. Liver transplantation in HIV/hepatitis coinfection. J HIV Therapy 2007; 12:24-35. An up-to-date and comprehensive review summarizing the available data on OLT in HIV-infected patients.
63. Wojcik K, Vogel M, Voigt E, et al. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. AIDS 2007; 21:1363-1381.